PARP inhibitors can induce synthetic lethality in tumors characterized by homologous recombination deficiency (HRD), which can be detected by evaluating genome-wide loss of heterozygosity (LOH). Here, PARP1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.